Page 57 - BSAVA Guide to Pain Management in Small Animal Practice
P. 57

BSAVA Guide to Pain Management in Small Animal Practice



        VetBooks.ir  fewer side e ects than other opioids although it   intravenous bolus or infusion (its short duration
           can cause dysphoria in dogs. It frequently
                                                  of action limits its usefulness by the
                                                  intramuscular route). Fentanyl transdermal
           causes euphoria in cats, and can be used to
           improve cooperation in some feline patients.  patches (unlicensed) have been used in both
              Buprenorphine has a bell shaped dose   dogs and cats, and can provide analgesia for
           response curve in some species (in theory it   several days.
           could antagoni e its own e ect at higher doses ,   The injectable solution can be used in both
           so practitioners are often reluctant to use it to   dogs and cats as a co-induction agent and to
           e ect.  owever, the plateau of the curve occurs   provide intra- and postoperative analgesia.
           at doses much higher than those used clinically    nset of action is less than   minutes when
             .  mg kg in rats,  um and  er , 1981 .   administered as a bolus, making fentanyl very
           Therefore, the bell-shaped curve is not clinically   useful for providing analgesia in response to
           relevant and supplemental doses can be given   surgical stimulation intraoperatively. If surgical
           (and are licensed).                    stimulation is sustained, an intravenous infusion
              Buprenorphine can be used to partially   can be administered, and the dose rate titrated
           antagoni e the e ects of a full   P agonist.  or   to e ect; additional boluses can be given as
           example, if a patient is dysphoric or over-  necessary. Concerns about accumulation of
           sedated following the administration of a MOP   fentanyl during infusion seem to be unfounded
           agonist, buprenorphine can be administered to   based on a study that assessed the
           reduce these unwanted e ects while still   pharmacokinetics of a 1   g kg intravenous
           providing some analgesia. This is called   bolus followed by an infusion of 1   g kg hour
           sequential analgesia and has been      for up to 4 hours  Sano et al.,    6 .  uring
           demonstrated in humans and in rabbits sedated   general anaesthesia, administration of a
           with fentanyl  uanisone   lecknell et al., 1989 .  fentanyl bolus or infusion can cause
                                                  bradycardia, respiratory depression or even
           Fentanyl: Fentanyl is a full MOP agonist with a   apnoea. It is advisable to discontinue fentanyl
           rapid onset and short duration of action at the   infusion at least    minutes before the end of
           doses commonly used clinically. The doses   anaesthesia to avoid respiratory depression in
           recommended in  igure  .  are lower than the   the recovery period. Respiratory depression is
           licensed doses, but the authors have found   very unlikely to occur in conscious patients.
           them to be e ective. It is highly lipid soluble,   Fentanyl patches have been widely used to
           and resolution of its e ects may be due to   provide long-term analgesia in dogs and cats
           redistribution rather than metabolism. At higher   although they are unlicensed. An area of
           doses it may accumulate. It is currently licensed   relatively immobile skin, for example, at the
           for dogs as a     g ml in ectable solution for   dorsal or lateral thorax should be clipped and

            Use of full MOP agonists following buprenorphine administration
             f an appropriate dose of  uprenorphine does not achieve the re uired analgesic effect, a full
            MOP agonist can be administered. It is still not clear if adjustment of the dose of the full agonist
            is required, and if so, whether an increase or decrease of the dose is appropriate. Whatever
            course of action is chosen, it is unlikely to harm the patient. Trial therapy with the usual dose of
            the full MOP agonist seems sensible; supplemental doses can be administered if necessary.
            Alternatively, the full MOP agonist could be administered in small intravenous increments until
            analgesia is achieved. In this situation it is also important to use multimodal analgesia as some
            types of pain may respond better to other classes of analgesics than to opioids. If use of a full
            MOP agonist for intraoperative analgesia is anticipated, for example, epidural morphine injection
            or fentanyl infusion, it makes sense to use a full MOP agonist in the pre-anaesthetic medication
            rather than buprenorphine.


           52



         Ch05 Pain Management.indd   52                                         19/12/2018   10:36
   52   53   54   55   56   57   58   59   60   61   62